Fact-checked by Grok 2 weeks ago

10x Genomics

10x Genomics, Inc. is an American life sciences technology company headquartered in , that develops and commercializes innovative instruments, consumables, and software for high-throughput analysis of biological systems at single-cell, spatial, and resolutions. Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, the company emerged from prior collaborations at QuantaLife, Inc., with a vision to accelerate through scalable tools. Its mission is to fuel scientific discoveries and advance human health by enabling researchers to master via precise, multidimensional data generation. The company's core offerings center on three integrated platforms: the system for single-cell and , which encapsulates thousands of cells or nuclei into gel beads for simultaneous expression, protein, and epigenetic profiling; the Visium platform for , allowing whole-transcriptome mapping on tissue sections at subcellular resolution; and the Xenium platform for analysis, which detects targets directly in intact tissues with customizable panels up to 5,000 targets. These technologies support diverse applications, including immune profiling, screens, and antigen specificity assays, and are compatible with fresh, frozen, or formalin-fixed paraffin-embedded (FFPE) samples across , , and other . Recent advancements, such as the GEM-X series for flexible single-cell workflows and Xenium Protein for combined RNA-protein detection, enhance and capabilities. Since its inception, 10x Genomics has grown rapidly, placing over 4,600 instruments in leading academic, biopharmaceutical, and clinical institutions worldwide, securing more than 1,750 patents, and contributing to over 10,000 peer-reviewed publications that have advanced fields like , , and . The company went public on the (ticker: TXG) in September 2019, acquired Scale Biosciences in August 2025 to integrate quantum barcoding and combinatorial indexing for multi-million cell scale single-cell analysis of protein, gene expression, and epigenetics, and continues to innovate, with ongoing expansions in partnerships and cloud-based tools to democratize access to complex biological insights.

Overview

Founding and leadership

10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness in . The company emerged from the founders' shared vision to create innovative solutions in , drawing on their prior experiences in and . Saxonov, who had served as a co-founder and executive at , brought strategic leadership; Hindson contributed expertise in single-cell technologies from his role at QuantaLife; and Ness provided engineering insights from his work at . From its inception, 10x Genomics focused on developing scalable tools for genomic analysis to accelerate biological discovery and enable researchers to tackle complex problems in biology. This initial emphasis aligned with the company's mission to deliver powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and advance human health. The company's headquarters remain in Pleasanton, California, where it employs approximately 1,306 people as of December 31, 2024. As of November 2025, Serge Saxonov continues to serve as , guiding the company's strategic direction and innovation efforts. Ben Hindson, a co-founder, holds the positions of and , overseeing scientific advancements and contributing to key inventions in genomic technologies based on his background in chemistry and . The executive team also includes Michael Schnall-Levin as , responsible for product development; Mennah Moustafa as , managing global sales and marketing; Adam Taich as , handling financial operations; Jim Goodrich as , directing operational efficiency; and Eric Whitaker as Chief Legal Officer, leading legal affairs. On November 12, 2025, Eric Whitaker announced his retirement effective January 1, 2026, to be succeeded by Dr. Randy Wu as Chief Legal Officer.

Corporate structure and operations

10x Genomics, Inc. is a publicly traded company listed on the under the TXG, having gone public in September 2019. The company's centers on the and sale of instruments, proprietary consumables, and software solutions designed exclusively for scientific applications, with no products approved or marketed for clinical or diagnostic use. 10x Genomics maintains its primary research and development (R&D) and manufacturing operations in , at its headquarters located at 6230 Stoneridge Mall Road, supplemented by a manufacturing and commercial hub in to enhance in the region. operates sales and support offices globally, including in (such as Leiden, Netherlands), (Shanghai, China, and ), and multiple locations across the (e.g., and , ). As of December 31, 2024, 10x Genomics employed 1,306 people worldwide, with approximately 92% of the based in the United States following an 8% global headcount reduction implemented in May 2025 to align with strategic priorities and reduce operating expenses. The company emphasizes diversity and inclusion initiatives, including ongoing efforts to foster a diverse and programs such as scholarships and fellowships aimed at supporting underrepresented groups in fields. 10x Genomics collaborates extensively with academic institutions and biotechnology firms to validate and advance its technologies, exemplified by partnerships with the for large-scale single-cell datasets to train models in , and with the Arc Institute and Ultima Genomics to develop comprehensive cell atlases using high-throughput sequencing.

Products and technologies

Single-cell analysis platforms

The Chromium platform, launched by 10x Genomics in 2016, represents a cornerstone of high-throughput single-cell RNA sequencing (scRNA-seq) technology. It enables the simultaneous analysis of thousands of individual cells by partitioning them into gel beads-in-emulsion (GEMs) using microfluidic chips, where each cell is paired with a barcoded gel bead containing oligonucleotides for unique molecular identification and transcript capture. This GEM-based approach allows for the generation of barcoded cDNA libraries from single cells, facilitating downstream sequencing to profile gene expression at cellular resolution without prior cell sorting. Key features of the Chromium platform include its ability to process up to 10,000 cells per sample in standard workflows, delivering high cell recovery rates and low doublet rates for reliable data. It supports diverse applications, such as dissecting immune cell heterogeneity in immunological studies, identifying rare tumor subpopulations in oncology research, and mapping neuronal diversity in neuroscience investigations. For instance, in oncology, Chromium data has revealed tumor microenvironment dynamics, aiding in the discovery of therapeutic targets. The platform has evolved to meet demands for greater scale and sensitivity. The X instrument, introduced in 2021, enhances throughput by enabling experiments with up to 80,000 s or more per run through improved and reagent delivery, supporting million-cell-scale analyses at reduced cost per . Further advancements came with GEM-X technology in 2024, which optimizes and capture to achieve up to 80% and 40% higher gene detection, particularly for low-input or challenging samples like fixed tissues. In October 2025, 10x Genomics launched the next generation of the Flex assay, featuring plate-based multiplexing and automation compatibility to enable processing of up to 384 samples or 100 million s per week, further scaling single-cell studies, and sponsored the Arc Institute Virtual Cell Challenge where winners utilized GEM-X Flex technology for high-quality single-cell data. Software tools are integral to the Chromium ecosystem for data processing and interpretation. Cell Ranger, a pipeline for alignment, quantification, and quality control, handles raw sequencing data to generate gene expression matrices, while Loupe Browser provides an intuitive interface for interactive visualization, clustering, and differential expression analysis. These tools integrate seamlessly with open-source platforms like Seurat, enabling researchers to explore datasets without extensive bioinformatics expertise. In October 2025, 10x Genomics partnered with Anthropic to integrate AI-driven analysis using Claude for Life Sciences, enhancing accessibility for single-cell and spatial data interpretation. As of 2025, the platform has driven significant scientific impact, with over 8,000 peer-reviewed publications leveraging its technology to advance fields from basic to clinical .

Spatial transcriptomics platforms

The platform, developed by 10x Genomics, enables spatially resolved whole-transcriptome analysis by capturing mRNA from sections onto arrays featuring barcoded spots, each approximately 55 microns in diameter, allowing mapping while preserving architecture. This technology originated from the 2018 acquisition of AB, with the commercial launch of Visium occurring in late 2019. The platform supports unbiased profiling of thousands of genes across fresh-frozen or fixed , integrating histological imaging such as H&E staining to correlate molecular data with morphological features. Key variants expand Visium's utility for diverse sample types and resolutions. Visium Spatial Gene Expression for FFPE, introduced in 2021, adapts the platform for formalin-fixed paraffin-embedded tissues using probe-based capture to overcome fixation-induced RNA degradation, enabling retrospective analysis of archived clinical samples. In 2024, Visium HD was launched, offering higher resolution with 2-micron spatial bins for near-single-cell-scale profiling, enabling detection of up to approximately 18,000 genes (whole transcriptome) and improving delineation of cellular heterogeneity. Applications of Visium have advanced understanding in and . In studies, it reveals spatial interactions between cancer cells, immune infiltrates, and stromal elements, such as identifying immunosuppressive niches in prostate . For , Visium maps gradients during embryogenesis, highlighting tissue patterning and cell fate transitions in model organisms. The Visium workflow begins with cryosectioning or processing of tissue samples (5-10 microns thick) onto specialized slides containing the capture array, followed by , permeabilization to release mRNA, and hybridization to spatial barcodes. Libraries are prepared via reverse transcription and amplification, then sequenced on Illumina systems to generate paired-end reads that include spatial barcodes and unique molecular identifiers. is performed using software, which aligns reads to a , deconvolutes spots into cellular contributions, and overlays expression data onto tissue images for visualization. A significant advancement, the Visium CytAssist instrument, released in 2022, automates the transfer of analytes from standard glass slides to capture arrays, reducing hands-on time to about 8 hours over 2-3 days and enabling processing of up to four samples in parallel for improved throughput and reproducibility.

In situ analysis platforms

The Xenium platform, launched in 2022, is an imaging-based (ISH) system developed by 10x Genomics for high-plex of in tissue sections. It enables the detection of up to 5,000 genes per sample, providing transcript-level mapping while preserving native tissue architecture. This technology supports both fresh frozen and formalin-fixed paraffin-embedded (FFPE) samples, facilitating high-throughput profiling with results available in as little as six days. Key features of the Xenium platform include subcellular at the nanometer scale, allowing precise localization of RNA transcripts within cells. It incorporates advanced decoding algorithms that assign gene identities to imaged signals using unique codewords, enhancing accuracy in multiplexed detection. In 2025, the platform expanded with Xenium Protein, enabling simultaneous and protein in the same section, with support for up to 27 protein markers via ready-to-use subpanels. This multiomic capability reveals correlations between and protein localization at single-cell . The platform finds applications in neurobiology, where it maps neuronal gene expression patterns to study brain disorders and cellular interactions, and in , particularly for profiling tumor microenvironments and immune responses in immuno-oncology contexts. Automated on the Xenium Analyzer instrument handles whole-slide acquisition with high speed, incorporating metrics and algorithmic error mitigation during transcript decoding to ensure reliable data. These features support detailed investigations into disease heterogeneity without tissue dissociation. The Xenium workflow begins with tissue sectioning onto specialized slides, followed by probe hybridization where gene-specific circular DNA probes bind to target transcripts. Subsequent and rolling circle amplification () generate localized fluorescent signals for each transcript. The prepared slide is then loaded into the Xenium Analyzer for sequential imaging cycles, capturing morphology, , and protein signals across the entire tissue section. This process integrates signal amplification and decoding onboard the instrument. Data analysis is facilitated by the Xenium Explorer software, a desktop application that provides interactive visualization of transcripts, segmented cells, and co-expression patterns without requiring advanced bioinformatics expertise. It supports overlaying and protein data for multiomic insights. As of 2025, Xenium integrates with workflows, allowing combined transcript and protein datasets to be analyzed alongside complementary spatial technologies like Visium for broader tissue-scale context.

History

Formation and early innovations

10x Genomics was founded in July 2012 as Avante Biosystems, Inc., in , by Serge Saxonov, Ben Hindson, and Kevin Ness, with initial operations focused on developing advanced tools. This initial capital supported the transition from conceptual designs to practical implementation, marking the inception of a platform aimed at enhancing the resolution and throughput of sequencing applications. Early research and development at 10x Genomics centered on to address limitations in traditional genomic workflows, particularly for applications requiring high-resolution analysis of complex samples. By 2013, the team had developed an initial prototype leveraging emulsion-based techniques to and process genetic material, laying the groundwork for scalable solutions. This innovation built on the founders' prior expertise in microfluidics and sequencing, though details remained during this pre-commercial phase. The focus was on creating systems that could the intricacies of next-generation sequencing, where competition from established like Illumina and emerging single-cell methods demanded improvements in throughput and cost-efficiency. In 2015, 10x Genomics launched its initial technology through the GemCode platform, introduced at the Advances in Genome Biology and Technology meeting, which enabled linked-read sequencing for structural variant detection. This marked the company's entry into the market, generating approximately $3 million in revenue that year from early adopters seeking enhanced genomic assembly capabilities. However, the nascent field presented challenges, including intense competition in next-generation sequencing tools and the need to scale microfluidic processes for reliable single-cell partitioning without compromising data quality or increasing costs. Between 2016 and 2018, 10x Genomics advanced its single-cell offerings with beta testing and early access programs for the platform, debuting in March 2016 to select researchers for feedback on droplet encapsulation and barcoding efficiency. Full commercial sales of the Single Cell Controller and associated Single Cell 3' Solution began later that year at the American Society of Human Genetics meeting, transitioning from prototype validation to widespread adoption in academic and biotech labs. This period solidified the company's emphasis on scalability, with iterative improvements addressing throughput limitations in single-cell applications amid a competitive featuring rivals like Fluidigm.

Expansion and public offering

In September 2019, 10x Genomics completed its (IPO) on the Global Select Market under the TXG, pricing 10 million shares at $39 each and raising approximately $390 million in gross proceeds. The IPO valued the company at around $3.6 billion and provided capital to support ongoing product development and global , with shares opening higher and closing at $52.75 on the first . At the time of the IPO, the company employed 584 people, primarily in , , and operations. Following the IPO, 10x Genomics experienced significant revenue growth, increasing from $245.9 million in to $618.7 million in 2023, largely driven by recurring sales of that complement its platforms. This trajectory reflected broader adoption of its single-cell and spatial technologies in academic, biopharma, and settings. By the end of 2023, the company had achieved over 5,966 cumulative installations worldwide, including more than 5,180 systems, underscoring the scalability of its . The period from 2020 to 2023 was marked by challenges from the , which disrupted funding and laboratory operations globally, yet also accelerated demand for 10x Genomics' tools in immunology . In response, the company pivoted toward enhancing its immune profiling capabilities, launching the V(D)J solution for in July 2020 to support studies of adaptive immune responses, including those related to SARS-CoV-2. This strategic focus helped mitigate funding shifts, contributing to sustained growth amid pandemic-related volatility. Concurrently, 10x Genomics expanded into the market, opening a and hub in in October 2021 to bolster and serve the region's growing , which accounted for about 25% of global sales by mid-2021. Employee headcount grew to 1,259 by December 31, 2023, supporting enhanced R&D (451 employees) and efforts.

Key acquisitions and product launches

In 2018, 10x Genomics made two significant acquisitions to enhance its technological capabilities in emerging fields of genomics. The company acquired Epinomics in August, gaining access to advanced ATAC-seq technology and intellectual property focused on epigenetics research, which aimed to accelerate discoveries in gene regulation and chromatin accessibility. Later that year, in December, 10x Genomics acquired Spatial Transcriptomics, a Stockholm-based pioneer in spatial genomics, for an undisclosed amount; this move integrated Spatial Transcriptomics' slide-based technology for mapping gene expression in tissue sections, strengthening 10x Genomics' portfolio in spatial biology. Building on the Spatial Transcriptomics acquisition, 10x Genomics launched the Visium Spatial Gene Expression platform in November 2019, marking its entry into commercial with an instrument-free workflow for whole-transcriptome analysis in intact s. In December 2022, the company debuted the Xenium platform, introducing high-throughput, subcellular-resolution imaging for up to 5,000 genes in samples, compatible with fresh and FFPE tissues via targeted panels. From 2023 to 2024, 10x Genomics advanced its spatial and single-cell offerings with several key product introductions and upgrades. In May 2023, it launched the Visium CytAssist instrument and associated gene and protein expression assay, enabling automated processing of standard glass slides for enhanced tissue profiling and integration with existing Visium workflows. In February 2024, the GEM-X technology was introduced as a major upgrade to the Chromium single-cell platform, featuring improved emulsion chemistry for higher cell capture efficiency and scalability in gene expression analysis. Later that year, in early 2024, Visium HD was released, providing near-single-cell resolution spatial transcriptomics with 2-micron pixel size for detailed gene expression mapping in FFPE samples. In October 2024, the GEM-X Flex was launched, offering plate-based multiplexing to process up to 384 samples or 100 million cells per week, reducing per-cell costs to as low as one cent and supporting large-scale studies across diverse sample types. In 2025, 10x Genomics continued its innovation momentum with launches emphasizing scalability and integration. In August, the company launched Xenium Protein, a extension to the Xenium platform that enables simultaneous detection of and proteins in the same tissue section using pre-designed subpanels for up to 30 proteins, facilitating deeper insights into cellular heterogeneity. These acquisitions and launches strategically bolstered 10x Genomics' spatial biology portfolio by incorporating complementary technologies and expanded its market share in single-cell and , contributing to sequential revenue growth in subsequent quarters.

Legal issues

Arbitration with Bio-Rad

In 2014, initiated an claim against the founders of 10x Genomics—Serge Saxonov, Benjamin Hindson, and Kevin Ness—alleging that they had breached non-compete, , and obligations stemming from their prior employment at QuantaLife, a company acquired by in 2011. The dispute centered on claims that the founders had misappropriated trade secrets and violated restrictive covenants by establishing 10x Genomics and developing competing droplet-based microfluidic technologies. The arbitration proceedings took place before the , where Bio-Rad sought to enforce the alleged breaches and potentially impose restrictions on the founders' activities at 10x Genomics. In a ruling issued in 2015, the arbitrator fully denied Bio-Rad's claims, determining that the founders had not breached any of the specified obligations and awarding no damages to Bio-Rad. Furthermore, the decision allowed the 10x founders to pursue recovery of their attorneys' fees and costs from the proceedings. The outcome of the arbitration cleared the founders of any wrongdoing, validating their right to operate 10x Genomics independently without ongoing restrictions from their prior employment agreements. This resolution removed a significant legal hurdle early in the company's development, enabling 10x Genomics to focus on commercializing its innovative single-cell and spatial genomics platforms.

Patent infringement disputes

In 2018, Bio-Rad Laboratories and the University of Chicago filed a patent infringement lawsuit against 10x Genomics in the U.S. District Court for the District of Delaware, alleging that 10x's Single Cell and Linked-Read genomics products infringed three patents related to droplet microfluidics technology licensed exclusively to Bio-Rad: U.S. Patent Nos. 9,689,025; 9,626,712; and 9,995,656. A jury found the infringement willful and awarded Bio-Rad approximately $24 million in damages, calculated based on a reasonable royalty rate of 15% on 10x's net revenues from the infringing products. The district court subsequently granted Bio-Rad's motion for a permanent injunction, which required 10x to pay a 15% royalty on net revenues from sales of certain installed base products until the patents expired, along with supplemental damages exceeding $10 million for post-verdict sales. In August 2020, the U.S. Court of Appeals for the Federal Circuit affirmed the jury's validity and infringement findings for one of the patents, upheld the damages award, and confirmed the willfulness determination, though it remanded for further proceedings on two other patents under a revised claim construction. The parties reached a global settlement in July 2021, under which 10x agreed to pay Bio-Rad $29.4 million in royalties and interest on GEM product sales, and both granted each other non-exclusive, royalty-bearing cross-licenses for single-cell technologies, resolving all ongoing litigations. From 2022 onward, 10x Genomics initiated several actions to protect its innovations in single-cell and , often involving acquired through company purchases such as Cartana and ReadCoor for and spatial technologies. In October 2022, 10x sued Parse Biosciences in federal court, claiming infringement of patents covering gel bead emulsion (GEM) technology for single-cell sequencing, including U.S. No. 10,851,394. The dispute escalated, with Parse challenging the validity of several 10x patents. On February 4, 2025, the Trial and Appeal Board invalidated all of 10x Genomics' patent claims asserted against Parse's core single-cell products. In February 2025, the court upheld the validity and infringement of 10x's patents (U.S. Nos. 10,577,722 and 11,299,737), leading to a injunction entered on March 3, 2025, that barred Parse from manufacturing, using, selling, or offering its planned ATAC products; the remaining trial claims were subsequently dropped. Later, Parse successfully invalidated claims in U.S. No. 11,028,752 for lack of written and enablement on October 9, 2025. In June 2023, 10x, along with , sued Vizgen in federal court for infringing patents on sequencing and analysis, including U.S. Nos. 10,408,590 and 10,557,201 licensed from Harvard's George Church lab, alleging Vizgen's MERFISH technology copied 10x's Xenium platform methods acquired via ReadCoor. Vizgen countersued, raising antitrust claims that were dismissed at in 2024. The case proceeded to trial in February 2025 but settled on , 2025, with terms undisclosed, ending all U.S. and European litigations and allowing Vizgen to continue operations under the agreement. 10x also pursued claims against NanoString Technologies (acquired by in 2024), filing suit in 2023 over patents, including those from the 2020 Cartana acquisition covering methods (e.g., U.S. No. 11,091,757). The parties resolved the disputes through a global settlement announced on May 14, 2025, in which agreed to pay 10x $68 million in quarterly installments from Q3 2025 to Q2 2026, plus ongoing royalties on NanoString's CosMx and GeoMx products, granting mutual cross-licenses for single-cell and spatial technologies. Most recently, on October 21, 2025, 10x Genomics, joined by Prognosys Biosciences and , filed two lawsuits in federal court against Illumina, alleging infringement of nine patents related to single-cell partitioning and , including U.S. Patent Nos. 10,865,428 and 11,066,773 from Prognosys (acquired by 10x in 2023) and others covering barcoding and multi-omics integration. The suits target Illumina's Visium and PIPseq platforms, as well as technologies from its 2024 acquisition of Fluent Biosciences, claiming willful infringement that threatens 10x's market leadership. As of November 2025, the cases remain ongoing, with no trial date set. These disputes have resulted in multiple favorable settlements for 10x Genomics, reinforcing its portfolio and generating over $100 million in payments while limiting competitors' offerings in single-cell and spatial markets, thereby shaping industry dynamics around licensed access to core technologies.

Financial performance

Revenue growth and profitability

In 2024, 10x Genomics reported of $610.8 million, representing a 1% decline from $618.7 million in 2023, primarily due to softer demand in and sectors amid macroeconomic pressures. The company recorded a net loss of $182.6 million for the year, an improvement from $255.1 million in 2023, driven by reduced operating expenses. Total assets stood at $918.6 million as of December 31, 2024. Entering 2025, the company's financial performance showed mixed quarterly trends, reflecting a recovery from the prior year's dip through core operations despite one-time items. In the first quarter, reached $154.9 million, up 10% year-over-year, though adjusted excluding license and royalty fees was $138.1 million, down 2%. The second quarter saw total of $172.9 million, boosted by a $27.3 million litigation , with core at $145.6 million. Third-quarter totaled $149.0 million, a 2% year-over-year decline but a 2% sequential increase from core second-quarter figures, with consumables contributing $127.9 million or approximately 86% of total . Net loss narrowed to $27.5 million in the third quarter, compared to $35.8 million in the prior-year period. Based on the Q4 guidance, full-year 2025 is projected to be approximately $630-634 million on a total basis, though core (excluding settlements) would be near 2024 levels. Profitability remained challenged by substantial investments, with quarterly R&D expenses around $61-66 million, projecting an annual spend exceeding $250 million, alongside gross margins averaging 67-72% across quarters due to product mix shifts and inventory adjustments. Key drivers include lumpy cycles, which accounted for about 12% of third-quarter , and the recurring consumables model, historically comprising 80% of overall to support steady from high-volume single-cell and spatial applications. Looking ahead, 10x Genomics anticipates fourth-quarter 2025 revenue of $154-158 million, implying 3-6% sequential growth and positioning full-year results near 2024 levels on a core basis. Growth is expected to accelerate in 2026 from launches like the next-generation Flex platform, enhancing throughput for and addressing prior demand softness in consumables.

Market position and stock history

10x Genomics holds a leading position in the single-cell market, as a key player among the top five companies that collectively control 70-75% of the product segment share as of 2025, driven by its platform's dominance in high-throughput applications. Key competitors include Illumina, which focuses on broader sequencing technologies; Becton Dickinson (), offering systems for ; and NanoString Technologies, specializing in via GeoMx and CosMx platforms. The company's market strength stems from its integrated workflows for single-cell sequencing and , capturing a consolidated segment where the top five players control 70-75% of the market. The company went public on September 12, 2019, pricing its at $39 per share and raising approximately $390 million, with shares closing at $52.75 on the first trading day. performance peaked at $202.37 per share in 2021 amid high investor enthusiasm for during the post-pandemic biotech boom. However, shares experienced significant , declining sharply in subsequent years due to broader biotech sector challenges, including constraints and economic pressures; by November 2025, the stock traded around $16-17 per share, reflecting a 92.5% drop from its peak. This downturn aligned with stalled revenue growth projections of 0-3% for 2025, exacerbating share price pressure. As of November 2025, 10x Genomics' hovered between $1.9 billion and $2.1 billion, positioning it as a mid-cap player in the life sciences tools sector. Analyst ratings remain mixed, with a "Hold" from 16 firms and an average price target of $15, emphasizing potential upside from spatial biology expansions like the Xenium platform despite ongoing profitability concerns. Stock movements in 2024-2025 were influenced by macroeconomic factors, including rising interest rates and reduced venture in biotech, contributing to sector-wide with TXG's exceeding 1.98. Positive catalysts included patent settlements, such as the May 2025 agreement with for $68 million in payments through 2026, which boosted investor confidence and led to a 5-10% share price increase following announcements. Similarly, resolutions with Vizgen in early 2025 cleared antitrust hurdles, supporting market perception of strengthened defenses. Looking ahead, analysts highlight 10x Genomics' focus on integration—combining single-cell with spatial and data—as a key driver for clinical translation in and , potentially expanding applications beyond into diagnostics by 2030. This strategic emphasis, alongside robust in spatial (up significantly in Q3 2025), positions the company for recovery amid a projected single-cell market expansion to $13.7 billion by 2030.

References

  1. [1]
    Our mission - 10x Genomics
    Our mission. We deliver powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health.Serge Saxonov · Kim Popovits · Adam Taich · Eric Whitaker
  2. [2]
    10X Genomics Inc Overview - GlobalData
    10X Genomics is a life science tech company developing genomics platforms, including single-cell and spatial analysis, for researchers and biopharma companies.
  3. [3]
    Serge Saxonov | 10x Genomics
    Serge Saxonov co-founded 10x Genomics in 2012. As the CEO, he defined the 10x vision and strategy, contributed to core inventions, and has led the company ...Missing: headquarters | Show results with:headquarters
  4. [4]
    Ben Hindson | 10x Genomics
    Ben Hindson has served as Chief Scientific Officer and Director of 10x Genomics since its founding in 2012. Prior to 10x Genomics, he was Co-founder and ...Missing: Kevin Ness
  5. [5]
    Stepping on the scale - BioCentury
    Apr 11, 2016 · Co-founders CEO Serge Saxonov, COO and CTO Kevin Ness and President and CSO Ben Hindson previously worked together at genetic analysis company ...
  6. [6]
    Products | 10x Genomics
    ### Summary of 10x Genomics Products and Technologies
  7. [7]
    Visium Spatial Assays | 10x Genomics
    The Visium HD assay has superior spatial fidelity compared to other commercially available sequencing-based spatial transcriptomics platforms.
  8. [8]
    Xenium In Situ Platform | 10x Genomics
    Unparalleled single cell spatial discovery ; Gene and protein panels. Customizable ready-to-use panels or fully custom gene panels with add-on protein subpanels ...
  9. [9]
    The neXt generation of single cell RNA-seq: An introduction to GEM ...
    Mar 11, 2024 · GEM-X is an advanced technology for single-cell RNA-seq, improving upon previous methods with optimized reagents, microfluidics, and software.Missing: 2016 | Show results with:2016
  10. [10]
    10x Genomics Launches Xenium Protein, Advancing Spatial Biology ...
    Aug 19, 2025 · Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and ...
  11. [11]
    10X Genomics - Crunchbase Company Profile & Funding
    10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that ...
  12. [12]
    SPT Labtech and 10x Genomics Partner to Automate Single Cell ...
    Oct 14, 2025 · Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and ...<|control11|><|separator|>
  13. [13]
    Who Owns 10X Genomics Company? – MatrixBCG.com
    Sep 3, 2025 · 10X Genomics was established in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness. Their collective aim was to advance genomics technologies, ...
  14. [14]
    A message from our Co-Founders: Our commitment to innovation
    Mar 12, 2024 · We started this company because we believed we could do meaningful work, take on really hard problems and bring valuable tools to researchers ...
  15. [15]
    10x Genomics (TXG) Number of Employees - Stock Analysis
    10x Genomics Employees​​ 10x Genomics had 1,306 employees as of December 31, 2024. The number of employees increased by 47 or 3.73% compared to the previous year.
  16. [16]
    [PDF] 10x Genomics, Inc.
    Jun 3, 2025 · As such, Serge Saxonov serves as our Chief Executive Officer and Benjamin Hindson serves as our President while John. Stuelpnagel serves as ...
  17. [17]
    10x Genomics (TXG) Research Report - StockStory
    The company's business model involves selling instruments that run exclusively with its proprietary consumables and software. A typical customer workflow ...2. Summary · 3. 10x Genomics (txg)... · Company Overview<|separator|>
  18. [18]
    10x Genomics: Decoding Biology. Transforming Health.
    We deliver powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health.
  19. [19]
    10x Genomics Celebrates Opening of Singapore Manufacturing and ...
    Oct 25, 2021 · 10x Genomics selected Singapore as the ideal location for its expansion because of the Singapore government's demonstrated commitment to the ...Missing: R&D | Show results with:R&D
  20. [20]
    10X Genomics Headquarters and Office Locations - Craft.co
    Locations ; United States, San Francisco, Three Embarcadero Center #2330 ; China, Shanghai, 1018 Chang Ning Lu, Chang Ning Qu ; Netherlands, Leiden, Dellaertweg 9D.Missing: global | Show results with:global
  21. [21]
    10x Genomics Office Locations and Headquarters: Pleasanton, CA
    10x Genomics corporate headquarters and office locations · Pleasanton, CA · Phoenix, AZ · San Diego, CA · San Francisco, CA · Denver, CO · Washington, DC · Atlanta, GA.Missing: global | Show results with:global<|separator|>
  22. [22]
    What is the Growth Strategy and Future Prospects of 10x Genomics?
    Sep 3, 2025 · These include a planned reduction of over $50 million in operating expenses for 2025 and an 8% reduction in its global workforce. The focus ...
  23. [23]
    [PDF] 10x Genomics, Inc.
    We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our ...
  24. [24]
    10x Genomics Fellowship Program launch 2025 - YouTube
    Mar 11, 2025 · ... diversity and functionality. By examining the gene expression profiles of individual cells, researchers can identify rare cell subsets ...
  25. [25]
    Chan Zuckerberg Initiative Launches Billion Cells Project with 10x ...
    Feb 6, 2025 · CZI is embarking on this landmark initiative in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading researchers.
  26. [26]
    10x Genomics and Ultima Genomics partner with Arc Institute to ...
    Apr 28, 2025 · The partnership aims to accelerate the Arc Virtual Cell Atlas development, using 10x and Ultima technologies to generate high-quality, large- ...Missing: biotech | Show results with:biotech
  27. [27]
    ASHG 2016 Round-up - 10x Genomics
    Oct 31, 2016 · We kicked off the week with an announcement about our new Chromium Single Cell Controller that brings affordable single cell analysis to any lab ...
  28. [28]
    Chromium GEM-X Technology - 10x Genomics
    Chromium GEM-X uses a microfluidic chip to generate Gel Beads-in-emulsion (GEMs) where target molecules are captured and barcoded, automating partitioning and ...Missing: 2016 | Show results with:2016
  29. [29]
    Chromium Next GEM Single Cell 5' HT v2: Reagents, Workflow ...
    Aug 9, 2021 · Chromium Next GEM Single Cell 5' HT v2 is a high throughput solution on the Chromium X series instrument for analyzing hundreds of thousands ...
  30. [30]
    Chromium Single Cell Applications | 10x Genomics
    Explore 8,000+ peer-reviewed publications by 10x Genomics users. Jump to: Whole transcriptome coverage. Protein coding gene coverage. Chromatin accessibility.
  31. [31]
    Publications | 10x Genomics
    See the latest publications using 10x Genomics. Read about exciting discoveries in single cell sequencing for gene expression profiling, immune profiling, ...
  32. [32]
    Increasing the power of single cell resolution with expanded ...
    Jul 27, 2021 · We recently announced the launch of our new Chromium X single cell instrument. Find out how this highly flexible system expands the reach of ...
  33. [33]
    Chromium Single Cell Analysis Software - 10x Genomics
    Cell Ranger processes data, performs QC, and quantifies gene expression. Loupe Browser visualizes data, and LoupeR integrates with Seurat analysis.
  34. [34]
    Visium Spatial Platform | 10x Genomics
    The Visium platform delivers unbiased, whole transcriptome spatial gene expression analysis at single cell scale with unmatched spatial data quality.Best-In-Class Spatial Data... · Visium Hd Wt Panel · New! Visium Hd 3'
  35. [35]
    10x Genomics acquires Spatial Transcriptomics - SciLifeLab
    Dec 20, 2018 · 10x genomics has announced their acquirement of Spatial Transcriptomics, an enterprise built around the technology with the same name and in large part ...<|separator|>
  36. [36]
    10x Genomics debuts gene expression mapping tech - Fierce Biotech
    Nov 26, 2019 · Last year, 10x Genomics jumped into the emerging field of spatial genomics through its buyout of Sweden's Spatial Transcriptomics.
  37. [37]
    Spatial Gene Expression for FFPE | Official 10x Genomics Support
    Visium Spatial Gene Expression measures the whole transcriptome of FFPE tissue sections in a spatially resolved manner by mapping gene expression over a ...Missing: variant | Show results with:variant
  38. [38]
    10x Genomics Commercially Launches Visium HD Spatial Gene ...
    Mar 26, 2024 · Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution.
  39. [39]
    Advances in spatial transcriptomics and its applications in cancer ...
    Jun 20, 2024 · It also discusses how to employ spatial transcriptomics to investigate tumor microenvironments and tumor heterogeneity and facilitate anti- ...Missing: developmental | Show results with:developmental
  40. [40]
    Spatial transcriptomics in development and disease
    Oct 9, 2023 · Spatial whole transcriptome profiling of the tumor microenvironment in FFPE prostate carcinoma using the Visium platform. J Immunol. 2022 ...<|separator|>
  41. [41]
    Visium Spatial Analysis Software | 10x Genomics
    Translate sequencing data into gene expression-aligned images. Space Ranger is a set of analysis pipelines that process Visium Spatial Gene Expression data with ...Missing: workflow | Show results with:workflow
  42. [42]
    Best in Class Slide Instrument: Visium CytAssist - 10x Genomics
    The Visium CytAssist enables users to start with tissue on standard glass slides, allowing input tissue to be prepared, stained, and imaged using standard ...Missing: 2023 | Show results with:2023
  43. [43]
    Optimizing your spatial transcriptomics research with Visium HD and ...
    Apr 8, 2024 · The Visium HD workflow itself requires roughly 8 hours of hands-on time over 2–3 days, and can be parallelized depending on the availability of ...
  44. [44]
    10x Genomics Commercially Launches Xenium Platform for In Situ ...
    Dec 9, 2022 · With the launch of the Xenium Analyzer, 10x Genomics is introducing two targeted panels, compatible with a broad range of fresh frozen and FFPE ...
  45. [45]
    Overview of Xenium Algorithms | Official 10x Genomics Support
    Then, probe hybridization, ligation, and rolling circle amplification (RCA) are performed following the steps in the respective assay user guides. Once the ...Onboard Analysis Pipeline · Image Processing · Transcript Decoding
  46. [46]
    What single cells are revealing about brain disorders
    Jul 11, 2025 · 10x's platforms – Chromium, Visium and Xenium – are all designed to study biology at cellular resolution, but each does so in a different way.
  47. [47]
    High resolution mapping of the tumor microenvironment using ...
    Dec 19, 2023 · We use Visium CytAssist to obtain whole transcriptome spatial data. Xenium provides subcellular spatial resolution, which is particularly suited ...Missing: developmental | Show results with:developmental
  48. [48]
    In Situ Chemistry & Transcriptomics Technology | 10x Genomics
    How it works. Once tissue sections are prepared on Xenium slides the chemistry workflow consists of probe hybridization, ligation, and enzymatic amplification.
  49. [49]
    S-1 - SEC.gov
    The “10x” in our name refers to our focus on opportunities with the greatest potential for exponential advances and impact. We believe that the scientific and ...
  50. [50]
    10X Genomics | Golden
    On November 1, 2012 10X Genomics completed their seed funding round with $4.7 million in funding from Silicon Valley Bank. On November 8, 2013 10X Genomics ...Missing: history | Show results with:history
  51. [51]
    10x Genomics – Foresite Capital
    10x Genomics has pioneered commercialization of single cell sequencing. We made our first investment in 10x Genomics in the Series A financing in November ...Missing: seed funding Founders
  52. [52]
    How successful tools companies closed their first deal? - Axial
    Dec 13, 2019 · With revenues nearly increasing 10X from ~$3M in 2015 to ~$27M in 2016, 10X's GemCode platform was gaining the traction necessary to compel ...Missing: GEM | Show results with:GEM
  53. [53]
    10X Genomics Dominates the Single-Cell Landscape While ...
    Apr 14, 2020 · Limited short-term clinical applications. For an in-depth analysis of the SCG market, see DeciBio's updated Single Cell Genomics report, with ...
  54. [54]
    10x Genomics Announces Commercial Availability of Single Cell 3 ...
    This is the first commercially available product announcement in a series of anticipated product releases for the 10x Genomics Chromium Platform, a suite of ...Missing: beta 2016-2018 sales
  55. [55]
    10x Genomics Announces Pricing of Initial Public Offering
    Sep 12, 2019 · The shares are expected to begin trading on the Nasdaq Global Select Market on September 12, 2019 under the symbol “TXG” and the offering is ...
  56. [56]
    424B4 - SEC.gov
    co-founded 10x Genomics in July 2012 and has served as our Chief Scientific Officer and President since October 2012 and has served on our board of ...<|separator|>
  57. [57]
    https://www.sec.gov/Archives/edgar/data/1770787/000119312519224368/d737378ds1.htm
  58. [58]
    10-K - SEC.gov
    Feb 27, 2020 · We changed our name to 10X Technologies, Inc. in September 2012 and to 10x Genomics, Inc. in November 2014. Our principal executive offices are ...Missing: count | Show results with:count
  59. [59]
    [PDF] 10x Genomics Reports Fourth Quarter and Full Year 2019 Financial ...
    Feb 18, 2020 · Revenue was $245.9 million for the year ended December 31, 2019, a 68% increase from $146.3 million for 2018. Gross margin was 75% for full year ...Missing: exact | Show results with:exact
  60. [60]
    [PDF] 10x Genomics Reports Fourth Quarter and Full Year 2023 Financial ...
    Feb 15, 2024 · Increased cumulative instruments sold to 5,966 as of the end of 2023, comprising 5,180 Chromium instruments, 531. Visium instruments and 255 ...Missing: installations | Show results with:installations
  61. [61]
    [PDF] 10x Genomics, Inc.
    Feb 15, 2024 · Aggregate market value of registrant's common stock held by non-affiliates of the registrant, based upon the closing price of a share of the ...
  62. [62]
    10x Genomics Provides COVID-19 Business Impact Update and ...
    Apr 9, 2020 · The company plans to provide final financial results and additional information related to the impact of COVID-19 on its upcoming earnings call, ...
  63. [63]
    10x Genomics Launches Next Generation Immune Profiling Product ...
    Jul 14, 2020 · 10x Genomics Launches Next Generation Immune Profiling Product to Combat COVID-19Delivers major improvements for discoveries in immunology, ...<|control11|><|separator|>
  64. [64]
    SoftBank-backed 10x Genomics buys Epinomics - CNBC
    Aug 28, 2018 · 10x Genomics is making its first acquisition of a start-up, called Epinomics; That puts it in a position to sell tools to researchers to help ...Missing: Transcriptomics | Show results with:Transcriptomics
  65. [65]
    10x Genomics Acquires Spatial Transcriptomics - PR Newswire
    Dec 10, 2018 · 10x Genomics today announced the acquisition of Stockholm-based Spatial Transcriptomics, a pioneer in the emerging field of spatial genomics.
  66. [66]
    10x Genomics Begins Shipments of Visium Spatial Gene
    Nov 26, 2019 · The Visium Spatial Gene Expression Solution is the first new product to result from 10x Genomics' acquisition of Sweden's Spatial Transcriptomics.
  67. [67]
    10x Genomics Commercially Launches Xenium Platform for In Situ ...
    Dec 8, 2022 · With the launch of the Xenium Analyzer, 10x Genomics is introducing two targeted panels, compatible with a broad range of fresh frozen and FFPE ...
  68. [68]
    10x Genomics Launches Visium CytAssist Gene and Protein ...
    May 24, 2023 · The instrument, launched in 2022, streamlines the Visium workflow by allowing expanded sample access, simplifying sample handling and improving ...
  69. [69]
    10x Genomics Expands Leadership in Single Cell Analysis with ...
    Feb 7, 2024 · The first major overhaul to the Chromium architecture since the 2019 launch of Next GEM technology, GEM-X is built on a new and improved ...
  70. [70]
    https://www.biospace.com/10x-genomics-launches-next-generation-immune-profiling-product-to-combat-covid-19delivers-major-improvements-for-discoveries-in-immunology-oncology-autoimmunity-and-infectious-diseases
  71. [71]
    10x Genomics Unveils Innovation Roadmap at AGBT General ...
    Feb 23, 2025 · "Our 2025 roadmap will once again raise the bar for the field and enable researchers to tackle bigger questions, analyze more samples and ...
  72. [72]
    https://www.prnewswire.com/news-releases/10x-genomics-acquires-spatial-transcriptomics-300762546.html
  73. [73]
    10X Genomics Founders Prevail in Arbitration Dispute With Bio-Rad
    Dec 21, 2015 · Bio-Rad brought a claim before the American Arbitration Association in 2014, alleging that three 10X Genomics founders breached certain ...Missing: 2014 | Show results with:2014
  74. [74]
    Bio-Rad, 10x Genomics settle genomics patent war | Reuters
    Jul 27, 2021 · The arbitrator ruled for 10x in 2015. Since then, the companies have sued each other in several venues over patented technology to isolate ...
  75. [75]
    Bio-Rad and the University of Chicago Win Patent Infringement ...
    Nov 14, 2018 · In awarding Bio-Rad $23.9 million in damages, the jury unanimously found that all Single Cell and Linked-Read genomics products sold by 10X ...
  76. [76]
    Bio-Rad Laboratories, Inc. v. 10X Genomics Inc., No. 19-2255 (Fed ...
    This technology has applications in medical diagnostics and high-throughput screening. In an infringement suit, the jury found all three patents valid and ...Missing: arbitration | Show results with:arbitration
  77. [77]
    Jury Awards $24 Million to Bio-Rad, 10x Genomics Infringement Willful
    Nov 26, 2018 · A jury in Delaware delivered a verdict awarding nearly $24 million dollars in reasonable royalty damages to plaintiffs Bio-Rad Laboratories ...Missing: arbitration | Show results with:arbitration
  78. [78]
    Bio-Rad Labs., Inc. v. 10X Genomics Inc. United States Court of ...
    [The court affirmed the jury's verdict awarding Bio-Rad almost $24 million in damages—the full requested amount based on a reasonable royalty rate of 15%.] ...
  79. [79]
    Court Enters Permanent Injunction and $34 Million Judgment for Bio ...
    Aug 19, 2019 · Court Enters Permanent Injunction and $34 Million Judgment for Bio-Rad Against 10X Genomics ... 15% royalty on 10X's net revenue from such sales.
  80. [80]
    10x Genomics IPO Starts Out Strong, as Bio-Rad Files Third Patent ...
    Sep 12, 2019 · The additional $10 million consisted of $8,341,368 in supplemental damages based on a 15% royalty ... In an Update and Supplement to Preliminary ...
  81. [81]
    The United States Court of Appeals for the Federal Circuit Affirms ...
    Aug 4, 2020 · “We are pleased that the Appeals Court upheld the District Court's finding that 10x willfully infringed Bio-Rad's intellectual property rights ...Missing: 2015 | Show results with:2015
  82. [82]
    10x Genomics, Inc. (Form: 8-K, Received - EDGAR Online
    Jul 27, 2021 · Pursuant to the Agreement, the Company shall pay Bio-Rad $29.4 million in royalties and interest related to the sales of such GEM products ...
  83. [83]
    Bio-Rad and 10x Genomics Announce Settlement to Resolve ...
    Jul 27, 2021 · Bio-Rad and 10x Genomics, Inc. (Nasdaq: TXG) have reached a final settlement to resolve multiple long-running litigations in Massachusetts, Delaware, ...Missing: 2015 | Show results with:2015
  84. [84]
    10x Genomics Secures Injunction Against Parse Biosciences ...
    Mar 3, 2025 · Following entry of the injunction, the trial scheduled for March 2025 concerning 10x's remaining patent infringement claims against Parse has ...
  85. [85]
    Parse Biosciences Invalidates Scale Biosciences (now 10x ...
    The Court concluded that the claims of the '752 patent were invalid for lack of written description and lack of enablement. About Parse ...
  86. [86]
    10x Genomics secures injunction against Parse Biosciences
    Mar 3, 2025 · The injunction, which was agreed upon on February 25, 2025, prohibits Parse Biosciences from manufacturing, using, selling, or offering to sell ...
  87. [87]
    Harvard, 10x Genomics Settle Patent Dispute With Vizgen | News
    Feb 22, 2025 · 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022.
  88. [88]
    10x Genomics and Harvard Overcome Patent and Antitrust Hurdles ...
    Feb 26, 2025 · 10x is also scheduled for a March 2025 trial against Parse Biosciences, Inc. ... infringed a series of patents related to 10x's “single ...
  89. [89]
    Notable Successes - Tensegrity Law Group
    Mar 19, 2025 · Tensegrity and 10x had previously won dismissal at summary judgment of Vizgen's antitrust counterclaims against 10x, in which Vizgen had sought ...
  90. [90]
    10x, Harvard settle genomics patent dispute with Vizgen during trial
    Feb 6, 2025 · Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled ...
  91. [91]
    Vizgen Announces End of Litigation with 10x Genomics and Harvard ...
    Mar 4, 2025 · On February 5 th , we secured an important settlement putting an end to litigation, including cases in the US and Europe, with 10X Genomics and Harvard ...
  92. [92]
    Bruker to Pay 10x Genomics $68M Under Global Settlement of ...
    Bruker to Pay 10x Genomics $68M Under Global Settlement of Patent Disputes. May 14, 2025 | staff reporter. Save for later.
  93. [93]
    10x Genomics Secures $68M Patent Settlement From Bruker
    May 14, 2025 · Under the settlement terms, Bruker will pay $68 million in equal quarterly installments between Q3 2025 and Q2 2026, plus ongoing royalties on ...
  94. [94]
    10x sues rival Illumina over gene-sequencing patents | Reuters
    Oct 21, 2025 · Biotech company 10x Genomics filed two lawsuits against rival Illumina in Delaware federal court on Tuesday, accusing Illumina of infringing ...
  95. [95]
    10x Genomics and Prognosys Biosciences Allege Illumina Infringed ...
    Oct 23, 2025 · Illumina's alleged infringing activities were detailed, stemming from its February 2025 announcement of a “spatial technology program” and ...
  96. [96]
    10X Genomics, Inc. et al v. Illumina, Inc. - Justia Dockets
    Oct 21, 2025 · Defendant: Illumina, Inc. Case Number: 1:2025cv01287. Filed: October 21, 2025. Court: U.S. District Court for the District of Delaware.
  97. [97]
    10x Settles Bruker, Vizgen Patent Lawsuits
    May 18, 2025 · 10x Genomics has settled patent infringement lawsuits with a pair of rivals, Bruker and Vizgen, through settlements that could reshape competition.
  98. [98]
    10x Genomics to Sue Illumina Alleging Infringement of Single-Cell ...
    Oct 21, 2025 · 10x Genomics to Sue Illumina Alleging Infringement of Single-Cell, Spatial Patents. Oct 21, 2025 | Andrew P. Han. Save for later.
  99. [99]
    10x Genomics Reports Fourth Quarter and Full Year 2024 Financial ...
    Feb 12, 2025 · Net loss was $182.6 million for full year 2024, as compared to a net loss of $255.1 million for 2023. Cash and cash equivalents and ...
  100. [100]
    https://www.genomeweb.com/business-news/bruker-pay-10x-genomics-68m-under-global-settlement-patent-disputes
  101. [101]
    10x Genomics Reports First Quarter 2025 Financial Results
    May 8, 2025 · Revenue was $154.9 million for the first quarter of 2025, a 10% increase from $141.0 million for the corresponding prior year period.
  102. [102]
    Press Release dated August 7, 2025. - SEC.gov
    Aug 7, 2025 · This guidance reflects approximately $4.0 million of revenue that resulted from customers in China accelerating purchases from the third quarter ...<|separator|>
  103. [103]
    [PDF] 10x Genomics, Inc.
    Aug 7, 2025 · Balance as of December 31, 2023. 119,095,362 $. 2 $. 2,025,890 ... This Mutual Arbitration Agreement (“Agreement”) is between the employee (“ ...
  104. [104]
    News - Investor Relations | 10x Genomics
    10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research ... 10x Genomics Expands Visium Platform ...
  105. [105]
    Global Single-Cell Sequencing Market to Reach USD 3.46
    Aug 21, 2025 · The market is consolidated, with five major players holding 70–75% of the product segment share: 10x Genomics (US) – Leader in pre ...
  106. [106]
    Leading Companies in Single Cell Sequencing Market - 10x ...
    Aug 25, 2025 · The single cell sequencing market is projected to reach USD 3.46 billion by 2030 from USD 1.95 billion in 2025, at a CAGR of 12.2% during ...
  107. [107]
    10x Genomics stock - buy in November 2025?
    The 10x Genomics stock reached its all-time high 55 months ago on 26/04/2021 at a stock price of 202.37 USD. Today, the stock price is 92.5% lower at 15.25 USD.
  108. [108]
    10x Genomics - 6 Year Stock Price History | TXG - Macrotrends
    The latest closing stock price for 10x Genomics as of November 07, 2025 is 15.25. An investor who bought $1,000 worth of 10x Genomics stock at the IPO in ...
  109. [109]
    10x Genomics: Is Single Cell Sequencing Too Niche? - Nanalyze
    Jun 10, 2025 · 10x Genomics is actively failing to grow not just one, but two product lines, even when they appear to be lowering prices.
  110. [110]
    10x Genomics Inc. Stock Quote (U.S.: Nasdaq) - TXG - MarketWatch
    10x Genomics Inc. ; Day Range 15.64 - 17.28 ; 52 Week Range 6.78 - 17.28 ; Market Cap $1.9B ; Public Float 110.42M ; Beta 1.98 ...TXG · Advanced Chart · Download TXG Data
  111. [111]
    10x Genomics (TXG) Stock Forecast and Price Target 2025
    Rating 3.8 · Review by MarketBeatBased on 16 Wall Street analysts who have issued ratings for 10x Genomics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 ...
  112. [112]
    Single cell & spatial multiomics for drug development - 10x Genomics
    Transforming drug development with single cell and spatial. Get high-resolution insights that will improve your odds of finding better targets.
  113. [113]
    https://www.globenewswire.com/news-release/2025/08/21/3137124/0/en/Global-Single-Cell-Sequencing-Market-to-Reach-USD-3-46-Billion-by-2030-MarketsandMarkets.html
  114. [114]
    10x Genomics to Acquire Scale Biosciences
    Official press release announcing the acquisition of Scale Biosciences by 10x Genomics on August 7, 2025, detailing the integration of technologies for advanced single-cell analysis.
  115. [115]
    10x Genomics to Acquire Scale Biosciences
    Announcement from Scale Biosciences' website confirming the acquisition and describing the technologies involved, including quantum barcoding and combinatorial indexing for multi-million cell scale analysis.
  116. [116]
    NeurIPS 2025: Altos Labs Wins Generalist Prize at Arc's Virtual Cell Challenge
    Article confirming 10x Genomics as sponsor of the Arc Institute Virtual Cell Challenge.
  117. [117]
    Virtual Cell Challenge 2025 Wrap-Up: Winners and Reflections
    Arc Institute announcement detailing winners' use of 10x Genomics GEM-X Flex technology for high-quality single-cell data.